Fetuin-A, an endogenous inhibitor of tyrosine kinases, binds to the extracellular domain of insulin receptors (IRs) and impedes the activation of IR signaling pathway by inhibiting IR autophosphorylation, resulting in decreased insulin sensitivity and glucose utilization, ultimately increasing the risk of type 2 diabetes 10-12. Here, INSR is linked to type 2 diabetes mellitus.